CN113842410A

CN113842410A - Pharmaceutical composition for slow transit constipation and preparation method and application thereof

Info

Publication number: CN113842410A
Application number: CN202111246551.2A
Authority: CN
Inventors: 张远哲; 黎豫川; 杨元凤
Original assignee: Guizhou University of Traditional Chinese Medicine
Current assignee: Guizhou University of Traditional Chinese Medicine
Priority date: 2021-10-26
Filing date: 2021-10-26
Publication date: 2021-12-28

Abstract

The invention relates to a pharmaceutical composition for slow transit constipation and a preparation method thereof, wherein the pharmaceutical composition consists of monkshood and cinnamon; the preparation method comprises soaking radix Aconiti lateralis Preparata and cortex Cinnamomi in clear water, decocting radix Aconiti lateralis Preparata, adding cortex Cinnamomi, decocting, filtering, mixing filtrates, concentrating to obtain medicinal liquid containing 1g crude drug per ml, and adding adjuvant to obtain preparation; the pharmaceutical composition has a significant effect on slow transit constipation.

Description

Pharmaceutical composition for slow transit constipation and preparation method and application thereof

Technical Field

The invention relates to the field of medicine invention, in particular to a pharmaceutical composition for slow transit constipation and a preparation method and application thereof.

Background

The slow transit constipation refers to non-organic constipation, prolonged defecation period and difficult defecation due to dysfunction and abnormal conduction of large intestine, and belongs to chronic, primary, functional, colonic and slow transit constipation.

Slow transit constipation causes the following causes: mainly because operating pressure is great, most people's diet life does not have the law, long-term bad habits and customs, for example it is irregular to live in, diet too meticulous, losing weight, the diet, lack to take exercise and lead to the intestinal to receive the stimulation not enough, the action of defecation lacks, excrement and urine is in the intestinal intracavity residence time for a long time, and enterokinesia is slow, needs two days, time three days even, just can transport food waste to the rectum, then, the patient just has the consciousness of defecation. Constipation has been reported to be caused by slow transit cases accounting for about 16% to 40% of constipation patients. Long-term slow transit constipation can easily cause hemorrhoids, rectal prolapse, colitis, intestinal obstruction, colon cancer and other diseases.

Slow transit constipation refers to constipation mainly caused by inflammatory changes and dysfunction, either of known or unknown causes. The clinical manifestations are abdominal pain, diarrhea, borborborygmus, tenesmus, stool with mucus or purulent blood, constipation or alternate dry and thin, lingering course of disease and recurrent attacks. Due to the disorder of digestive function and the lack of nutrient sources, patients can suffer from emaciation, anemia, weakness and even weakness. Severe cases often involve massive intestinal hemorrhage and intestinal perforation. Chronic colitis and irritable bowel syndrome have long course of disease, so the treatment is difficult, no specific medicine exists, and western medicine mainly uses antibiotics to diminish inflammation and relieve pain, resists infection and has large side effect; at present, although a lot of traditional Chinese medicines are used for treating slow transit constipation, the traditional Chinese medicines have the problem of poor treatment effect.

The invention discloses a traditional Chinese medicine for treating constipation, a preparation method and an application thereof, and has an application number of CN201310348797.X, and the invention name is the traditional Chinese medicine for treating constipation, and the preparation method and the application thereof are prepared from the following raw material medicines in parts by mass: 25-35 parts of monkshood; 5-15 parts of cinnamon; 15-25 parts of epimedium; 10-20 parts of magnolia officinalis; 15-25 parts of allium macrostemon; 25-35 parts of kudzu roots; 15-25 parts of poria cocos; the volatile oil is extracted from cinnamon, the cinnamon is included by beta-cyclodextrin to obtain an inclusion compound, other traditional Chinese medicines are refluxed by ethanol to prepare a preparation, and the preparation has the function of treating constipation, particularly the constipation caused by spleen-kidney yang deficiency.

The invention discloses a medicine for treating chronic constipation and a preparation method thereof, and the medicine comprises a plurality of Chinese herbal medicines such as radix scrophulariae, radix ophiopogonis, rhizoma cimicifugae, immature bitter orange, cooked monkshood, fried radish seed, cistanche, raw bighead atractylodes rhizome, Chinese angelica, elecampane, agilawood, fructus cannabis, platycladi seed, polygonum multiflorum, combined spicebush root, houttuynia cordata, raw astragalus mongholicus, mangnolia officinalis, wine-processed rhubarb, cinnamon, polygonatum odoratum, pericarpium arecae, honeysuckle, fructus forsythiae, radix clematidis, fructus gleditsiae and the like. Drying the medicines according to the formula, and grinding into powder; adding refined honey into the medicinal powder at a weight ratio of 1: 1.2-1.5, and making into pill. The medicine has the effects of benefiting qi, nourishing blood, clearing heat, removing dryness and relaxing bowel, has obvious curative effect on chronic constipation, particularly senile chronic constipation, is safe to use and has no side effect.

The invention discloses a pure traditional Chinese medicine preparation for treating constipation, which is a Chinese medicine preparation with application number CN200710116230.4, and is prepared by selecting more than twenty Chinese herbal medicines according to the essences of Chinese traditional medicines through years of trial and demonstration, wherein the Chinese traditional medicines have the following main clinical symptoms: the traditional Chinese medicine preparation has good treatment effects on symptoms of frequent defecation, dry defecation and sheep manure eggs, and is prepared from the following traditional Chinese medicines: fructus cannabis, sticky rice, eucommia ulmoides, mulberry, cristobalite, rheum officinale, monkshood, white cimicifugae foetidae, polygonatum, mangnolia officinalis, amber, senna leaf, mirabilite, radix scrophulariae, Lanhuashen, elecampane, combined spicebush root, cinnamon, aloe leaf, radix bupleuri, wax gourd, radix aconiti carmichaeli, dried rehmannia, long-noded pit viper leaf and raw polygonum multiflorum.

The technical problems of the above patents are as follows: 1) the medicine has more medicinal ingredients, complex preparation method and high cost, and is not beneficial to industrial production; 2) after the medicine is taken, the quantity and the water content of the excrement are not obviously changed, and the pathogeny is not fundamentally solved; 3) after administration, the effects on the 5-HT level in colon and intestinal blood serum are small; 4) long treatment time and poor effect.

In order to solve the problems, the inventor researches a pharmaceutical composition for slow transit constipation according to the properties of monkshood and cinnamon and by combining factors and kinetic factors generated by constipation, fundamentally solves the cause of colon, has positive effects on the influence of the pharmaceutical composition on the quantity and the water content of feces of STC rats, the carbon dust propulsion rate of the STC rats, the serum of the STC rats and the colon 5-HT level, and is beneficial to the treatment of the constipation.

Disclosure of Invention

The invention aims to provide a pharmaceutical composition for treating slow transit constipation.

Another object of the present invention is to provide a method for preparing a slow-transit constipation drug.

The invention also aims to provide application of the pharmaceutical composition in preparing a medicament for treating slow transit constipation.

The invention provides a pharmaceutical composition for slow transit constipation, which is characterized by comprising monkshood and cinnamon.

The raw materials of the invention preferably comprise the following medicines in parts by weight: 1-2 parts of monkshood and 0.5-1 part of cinnamon.

Preferably, the raw materials of the invention comprise the following medicines in parts by weight: 2 parts of monkshood and 1 part of cinnamon.

The preparation method of the pharmaceutical composition comprises the following steps:

1) respectively taking monkshood and cinnamon, and adding clear water to soak for 20-40 minutes;

2) decocting radix Aconiti lateralis soaked in 12-16 times of water for 50-90 min, adding cortex Cinnamomi soaked in water, decocting for 20-50 min, and filtering to obtain filtrate;

3) taking the filtered residue, adding 8-12 times of water, decocting for 20-40 minutes, and filtering to obtain filtrate for later use;

4) mixing filtrates, concentrating at 95-105 deg.C to obtain medicinal liquid containing 1g crude drug per ml, and adding pharmaceutically acceptable adjuvants to obtain pharmaceutically acceptable preparation.

Preferably, the first and second liquid crystal materials are,

1) respectively taking monkshood and cinnamon, and soaking in clear water for 25-35 minutes;

2) decocting radix Aconiti lateralis Preparata with 13-15 times of water for 55-80 min, adding cortex Cinnamomi, decocting for 30min, and filtering to obtain filtrate;

3) taking the filtered residue, adding 9-11 times of water, decocting for 25-30 minutes, and filtering to obtain filtrate for later use;

4) mixing filtrates, concentrating at 96-103 deg.C to obtain medicinal liquid containing 1g crude drug per ml, and adding pharmaceutically acceptable adjuvants to obtain pharmaceutically acceptable preparation.

It is further preferred that the first and second liquid crystal compositions,

1) respectively taking monkshood and cinnamon, and soaking in clear water for 30 minutes;

2) taking the soaked monkshood, adding 14 times of water, decocting for 60 minutes, adding the soaked cinnamon, decocting for 30 minutes, and filtering to obtain filtrate for later use;

3) taking the filtered residue, adding 10 times of water, decocting for 25 minutes, and filtering to obtain filtrate for later use;

4) mixing filtrates, concentrating at 100 deg.C to obtain medicinal liquid containing 1g crude drug per ml, and adding pharmaceutically acceptable adjuvants to obtain pharmaceutically acceptable preparation.

The auxiliary materials of the invention are one or more of starch, talcum powder, refined honey, simple syrup, sodium hydroxide, sodium benzoate and cane sugar.

The preparation is a solid preparation or a liquid preparation; the solid preparation is granules, capsules, tablets and pills; the liquid preparation is oral liquid or decoction.

The pharmaceutical composition provided by the invention is applied to the preparation of medicines for treating slow transit constipation.

The parts by weight referred to in the present invention may be units conventional in the art, and may be g, kg, etc.

Advantageous effects

1. The pharmaceutical composition of the invention has simple preparation method and low cost, and is beneficial to industrial production.

2. The invention is prepared by modeling medicine, and changes the feeding condition of a rat, the gloss of the skin and hair of the rat, the range of motion, the feeding amount and the body mass of the rat are respectively treated; observing the feces of the rats; an activated carbon push test; number of stool residues in colon; serum and the like were tested and the effectiveness of the drug of the present invention on colonic disorders was demonstrated by statistical analysis.

3. Through experiments on the influence of the quantity and the water content of the feces of STC rats, the results show that the quantity and the water content of the feces do not obviously change before and after normal modeling, and compared with the feces before modeling, the quantity and the water content of the feces in the modeling period of the monkshood-cinnamon 1 group, the monkshood-cinnamon 2 group, the accessory group, the cinnamon group, the mosapride group and the model group are obviously reduced (P is less than 0.05); compared with the modeling period, the numbers and the water contents of the feces of the rats of the monkshood-cinnamon 1 group, the monkshood-cinnamon 2 group, the monkshood group, the cinnamon group and the mosapride group are obviously increased (P is less than 0.05), and the model group has no obvious change and no statistical significance after treatment. Compared with the treatment period of the normal group, the number and the water content of the feces of the rats in the model group are obviously reduced, and the statistical significance is achieved (P is less than 0.05); compared with the treatment period of the model group, the number and the water content of the feces of rats in the monkshood-cinnamon 1 group, the monkshood-cinnamon 2 group, the monkshood group, the cinnamon group and the mosapride group are obviously increased.

4. Through experiments on the influence of STC rat carbon-point propulsion rate, the result shows that the model group rat carbon-point propulsion rate is reduced compared with the normal group (P < 0.05); compared with the model group, the carbon powder propulsion rate of rats with the compatibility of monkshood, cinnamon low, medium and high dose groups and the mosapride group is increased.

5. Through experiments on the influence of STC rat serum and colon 5-HT level, the result shows that compared with a blank control group, the serum 5-HT level of a model group is obviously increased (P is more than 0.05); after administration, compared with the model group, the blood serum 5-HT content of the aconite and cinnamon 2 group is obviously reduced (P is less than 0.05), and the blood serum 5-HT content of other administration groups is not obviously changed. Compared with a blank control group, the colon tissue content of the model group is obviously increased (P is less than 0.05); after administration, the colon tissue 5-HT content of each administration group has no obvious change compared with that of a model group, but the monkshood cinnamon 1 administration group has the tendency of reducing the colon tissue 5-HT.

Detailed Description

The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.

Example 1

The formula is as follows: 1000g of monkshood and 500g of cinnamon.

Example 2

The formula is as follows: 2000g of monkshood and 1000g of cinnamon.

The formulations of examples 1-2 were prepared according to any of the following methods.

Example 3

3) taking the filtered residue, adding 10 times of water, decocting for 30 minutes, and filtering to obtain filtrate for later use;

4) mixing filtrates, concentrating at 100 deg.C to obtain medicinal liquid containing crude drug 1g per ml, adding sodium benzoate 2g and sucrose 15g, bottling, and sterilizing to obtain decoction.

Example 4

1) Respectively taking monkshood and cinnamon, and soaking in clear water for 20 minutes;

2) decocting the soaked monkshood with 12 times of water for 50 minutes, adding the soaked cinnamon, decocting for 20 minutes, and filtering to obtain filtrate for later use;

3) taking the filtered residue, adding 8 times of water, decocting for 25 minutes, and filtering to obtain filtrate for later use;

4) mixing filtrates, concentrating at 95 deg.C to obtain medicinal liquid containing crude drug 1g per ml, adding sodium benzoate 2g and sucrose 15g, bottling, and sterilizing to obtain decoction.

Example 5

1) Respectively taking monkshood and cinnamon, and soaking in clear water for 40 minutes;

2) taking the soaked monkshood, adding 16 times of water, decocting for 90 minutes, adding the soaked cinnamon, decocting for 50 minutes, and filtering to obtain filtrate for later use;

3) taking the filtered residue, adding 12 times of water, decocting for 40 minutes, and filtering to obtain filtrate for later use;

4) mixing filtrates, concentrating at 105 deg.C to obtain medicinal liquid containing crude drug 1g per ml, adding sodium benzoate 2g and sucrose 15g, bottling, and sterilizing to obtain decoction.

Example 6

4) mixing the filtrates, concentrating at 98 deg.C to obtain medicinal liquid containing 1g of crude drug per ml, adding 500g of starch, mixing, granulating with 20 mesh sieve, drying at 80 deg.C for 1 hr, and grading to obtain granule.

Example 7

4) mixing the filtrates, concentrating at 96 deg.C to obtain medicinal liquid containing 1g of crude drug per ml, adding 500g of starch and 5% starch slurry, granulating, drying, and making into tablet.

Example 8

4) mixing the filtrates, concentrating at 100 deg.C to obtain medicinal liquid containing 1g of crude drug per ml, adding starch 300g and 0.5% pulvis Talci, mixing, oven drying, pulverizing, and encapsulating to obtain capsule.

Example 9

4) mixing filtrates, concentrating at 99 deg.C to obtain medicinal liquid containing 1g of crude drug per ml, adding 500g of starch, oven drying to obtain powder, adding 100g of refined honey per 100g of powder, and making into pill.

Example 10

4) mixing filtrates, concentrating at 96 deg.C to obtain medicinal liquid containing 1g crude drug per ml, adding simple syrup 100ml, 0.3% sodium benzoate, adjusting pH to 7.2 with 10% sodium hydroxide solution, stirring, standing, filtering, bottling, and sterilizing to obtain oral liquid.

In order to further verify the effectiveness of the invention, a series of verification tests are carried out, specifically as follows:

1. confirmation of preparation method

1.1 sources of composition ratios

According to the research on the influence of the leaf strength and the like on the monkshood and the cinnamon on the monkshood total alkaloids and the ester alkaloids, the effect regulation and control of the monkshood and the cinnamon in a ratio of 1:0.5 are most comprehensive, the total alkaloids can be increased, the ester alkaloids can be reduced to the maximum degree, and the content of the effective ingredients of the monkshood is well reserved. Therefore, monkshood is selected: cinnamon was in a ratio of 1: 0.5.

1.2 preparation method

Respectively taking monkshood and cinnamon, and soaking in clear water for 30 minutes; decocting the soaked radix Aconiti lateralis with 14 times of water for 60 min, adding the soaked cortex Cinnamomi, decocting for 30min, filtering, adding 10 times of water into the residue, decocting for 25 min, filtering, mixing filtrates, concentrating at 100 deg.C to 1:1 (i.e. 1g of crude drug per ml of medicinal liquid), and storing at 4 deg.C for use.

2. Experimental methods

2.1 Experimental animals

60 SPF male SD rats weighing 200 + -20 g were selected and provided by Chengdu Biotech company.

2.2 preparation of the drug

2.2.1 preparation of Molding Compounds

Compound diphenoxylate suspension: the compound diphenoxylate tablet is diluted into 0.1 g.L < -1 > suspension by using normal saline and is prepared as before use.

Activated carbon: hangzhou general Timber.

Electric heating constant temperature blast drier: shanghai Botai Equipment, Inc.

An electronic balance: suzhou Saynes instruments, Inc.

2.2.2 preparation of test drugs

Mosapride citrate suspension: the mosapride citrate tablet is diluted into 0.2 g.L < -1 > suspension by distilled water and is prepared as it is.

Selecting radix Aconiti lateralis Preparata from Sichuan Jiang oil producing area and cortex Cinnamomi from Guangxi producing area, and preparing into medicinal liquid according to the preparation method under item "1.2".

2.2.3 grouping and modeling

After 1 week of adaptive feeding of 60 rats, the rats were randomly divided into a blank group, a monkshood group and cinnamon, an accessory group, a cinnamon group, a mosapride group and a model group. The total number of the groups is 6, and n is 10 per group. Except the blank group, the other groups are subjected to intragastric administration according to 10 mg.kg-1 compound diphenoxylate suspension per day, the continuous intragastric administration is carried out for 21d, an STC model is prepared, and the general condition, the body mass, the stool grain number and the stool dry and wet mass of each group of rats are recorded per day during the molding period.

2.2.4 methods of administration

The blank group and the model group are administrated with 10 ml/(kg. d) -10.9% sodium chloride solution for intragastric administration, 1 time a day and 20 days continuously; the radix Aconiti lateralis, cortex Cinnamomi, and radix Aconiti lateralis Preparata are administered with the corresponding Chinese medicinal decoction concentrate with determined dosage, and the decoction is administered for 20 days continuously 1 time per day. The mosapride citrate group is administrated with 10 ml/(kg. d) -1 mosapride citrate suspension for intragastric administration, 1 time per day and 20 days continuously.

2.2.5 index detection

(1) General conditions are as follows: the changes of the feeding condition of the rats, the gloss of the fur, the range of motion, the feeding amount and the body mass of the rats are observed every day.

(2) And (3) observing feces of rats: before modeling, after modeling and after treatment of each group of rats, the excrement of the rats is observed respectively, the number of grains of the excrement of each group of rats is recorded, and the excrement character is observed at the same time to measure the water content of the excrement. And (3) drying the excrement at 90 ℃ by using an electrothermal constant-temperature incubator, respectively recording the weight of the excrement of the rat before and after drying, and calculating the water content of the excrement.

The moisture content of the excrement is (wet excrement mass-dry excrement mass)/wet excrement mass multiplied by 100 percent

(3) Activated carbon push-through test: preparation of activated carbon powder suspension: weighing 15g of edible lotus root starch, adding 100mL of water, boiling until the solution is transparent, weighing 5g of activated carbon powder, adding the solution, stirring uniformly, boiling to prepare an activated carbon suspension with the mass concentration of 5%, and refrigerating at low temperature for later use. The method comprises the following steps: after treatment of all groups of rats, fasting is performed for 24 hours without water prohibition, the prepared activated carbon suspension is used for gastric lavage of 10mL & kg-1, the rats are placed in a cage for movement after gastric lavage, and the rats are immediately killed by adopting a cervical dislocation method after 30 min. Immediately after the rat is killed, the abdominal wall is cut open, all intestinal tracts from the pylorus to the tail end of the rectum are dissociated and removed, the rat is placed on a measuring table in a tension-free state, the propelling length of the activated carbon in the intestinal tracts and the total length of the intestinal tracts are measured, and the propelling rate of the activated carbon is calculated.

The propelling rate of the activated carbon is equal to the propelling length of the carbon powder/the total length of the intestinal tract multiplied by 100 percent

Number of stool remaining in colon: the number of residual feces in the colon was counted for each rat.

(5) Serum: standing the femoral artery blood for 30min, centrifuging at 3000rpm for 10min, taking 100uL of serum, and storing the 5-HT to be detected in a refrigerator at-20 ℃; dissecting colon tissue, washing with 4 deg.C physiological saline, weighing 0.5g, making 10% homogenate with physiological saline, centrifuging at 3000rpm for 10min, collecting supernatant 100uL, and storing in refrigerator at-20 deg.C for 5-HT detection;

(6) statistical analysis

The measured data is averaged + -SD

It is shown that SPSS17.0 statistical analysis software is used to analyze and process data, and single-factor analysis of variance (one-way ANOVA) is used to compare between groups, and p <0.05 is used as difference, which has statistical significance.

3. Results of the experiment

3.1 Effect on the quantity and Water content of feces from STC rat

The quantity and the water content of the excrement before and after the normal molding are not obviously changed, and compared with the quantity and the water content before the molding, the quantity and the water content of the excrement in the molding period are obviously reduced (P is less than 0.05) when the monkshood, the accessory group, the cinnamon group, the mosapride group and the model group are matched with the cinnamon group; compared with the modeling period, the quantity and the water content of the feces of the rats of the aconite, the cinnamon and the mosapride groups are obviously increased (P is less than 0.05), and the model group has no obvious change and no statistical significance after treatment. Compared with the treatment period of the normal group, the number and the water content of the feces of the rats in the model group are obviously reduced, and the statistical significance is achieved (P is less than 0.05); compared with the treatment period of the model group, the numbers and water contents of the feces of the rats of the aconite, cinnamon and mosapride groups are obviously increased, and are shown in tables 1, 2 and 3.

TABLE 1 comparison of the excretion time of the first-particle black feces of rats before and after treatment

TABLE 2 influence of the water decoction of the combination of aconite and cinnamon on the defecation amount of STC rats at different time periods

Note that compared to the previous time point for the same group 1) P is less than 0.05; comparison with normal group 2) P < 0.05; p is less than 0.05 compared with the model group.

TABLE 3 influence of water decoction of radix Aconiti lateralis and cortex Cinnamomi on water content change of feces of STC rat at different time periods

Note that compared to the previous time point for the same group 1) P is less than 0.05; comparison with normal group 2) P < 0.05; comparison with model group 3) P < 0.05.

3.2 Effect on carbon dioxide push Rate in STC rats

Compared with the blank group of animals, the model group of animals has reduced carbon powder propulsion rate and has extremely obvious difference (P is less than 0.01); compared with the model group animals, the carbon powder propulsion rate of the rats in the treatment group is increased and has extremely obvious difference (P is less than 0.01), and the results are shown in a table 4.

TABLE 4 influence of the water decoction of the aconite and cinnamon drugs on the carbon propulsion rate of STC rats

Note that P <0.01 for the model group compared to the blank group; the remaining groups had, # # P <0.01 compared to the model group.

3.3 Effect on serum and colonic 5-HT levels in STC rats

Compared with the blank group, the 5-HT concentration in the serum of the rat in the model group is obviously reduced and remarkably different (P < 0.01). Compared with the model group, the blood serum 5-HT concentration of rats in the aconite, cinnamon and mosapride groups is obviously increased, and the difference is extremely obvious (P is less than 0.01); the 5-HT concentration in the serum of the rat with the accessory group is increased, and the difference is obvious (P < 0.05); the difference of the 5-HT concentration in the serum of the rats in other groups is not significant and has no statistical significance. Compared with the blank group, the 5-HT concentration in the colon homogenate of the rat in the model group is obviously reduced and remarkably different (P < 0.01). Compared with the model group, the 5-HT concentration in the colon homogenate of rats in the aconite, cinnamon, aconite and mosapride groups is obviously increased, and the difference is extremely obvious (P is less than 0.01); the differences in 5-HT concentrations in colon homogenates of the remaining groups of rats were not significant and were not statistically significant. The results are shown in Table 5.

TABLE 5 Effect of Combined Water decoction of radix Aconiti lateralis and cortex Cinnamomi on 5-HT levels in serum and colon of STC rat

Group of	N (only)	Serum 5-HT levels/ng/ml	Colonic 5-HT levels/ng/ml
				Is normal	10	9.059±1.569	3.492±0.310
Model (model)	10	5.374±1.545**	1.738±0.505**
				Radix Aconiti lateralis Preparata and cortex Cinnamomi	10	8.090±1.319##	3.273±0.363##
Auxiliary set	10	7.380±0.840#	2.816±0.389##
				Cinnamon group	10	6.644±1.099	2.089±0.291
Mosapride group	10	8.255±0.939##	3.178±0.215##

Note that P <0.05, P <0.01 for the model group compared to the blank group; the other groups compared with the model group, the # P is less than 0.05, and the # P is less than 0.01;

although the invention has been described in detail in the foregoing by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that various modifications and improvements can be made thereto without departing from the spirit of the invention.

Claims

1. A pharmaceutical composition for treating slow transit constipation is characterized by comprising monkshood and cinnamon.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises the following components in parts by weight: 1-2 parts of monkshood and 0.5-1 part of cinnamon.

3. The pharmaceutical composition of claim 2, wherein the raw materials consist of the following drugs by weight: 2 parts of monkshood and 1 part of cinnamon.

4. A process for preparing a pharmaceutical composition according to claims 1-3, wherein the process comprises:

5. The method of preparing the pharmaceutical composition of claim 4, wherein the method comprises:

4) mixing filtrates, concentrating at 96-103 deg.C to obtain medicinal liquid containing 1g crude drug per ml, and adding

Adding pharmaceutically acceptable adjuvants to make into pharmaceutically acceptable preparation.

6. The method of preparing the pharmaceutical composition of claim 4, wherein the method comprises:

4) mixing filtrates, concentrating at 100 deg.C to obtain medicinal liquid containing 1g crude drug per ml, and adding

The pharmaceutically acceptable auxiliary materials are prepared into pharmaceutically acceptable preparations.

7. The preparation method of the pharmaceutical composition according to any one of claims 4 to 6, wherein the adjuvant is one or more of starch, talcum powder, refined honey, simple syrup, sodium hydroxide, sodium benzoate and sucrose.

8. The method for preparing a pharmaceutical composition according to any one of claims 4 to 6, wherein the formulation is a solid formulation or a liquid formulation.

9. The method for preparing the pharmaceutical composition according to claim 8, wherein the solid preparation is granules, capsules, tablets, pills; the liquid preparation is oral liquid or decoction.

10. The pharmaceutical composition of any one of claims 1 to 3, wherein the pharmaceutical composition is for use in the preparation of a medicament for the treatment of slow transit constipation.